A Pilot Study of Mifepristone in Combat-Related PTSD by Golier, Julia A. et al.
Hindawi Publishing Corporation
Depression Research and Treatment
Volume 2012, Article ID 393251, 4 pages
doi:10.1155/2012/393251
Research Article
A Pilot Study of Mifepristone in Combat-Related PTSD
Julia A. Golier,1,2 Kimberly Caramanica,1 Rebecca DeMaria,1 andRachel Yehuda1,2
1Department of Psychiatry, James J. Peters VA Medical Center, Bronx, NY 10468, USA
2Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029-6574, USA
Correspondence should be addressed to Julia A. Golier, julia.golier@va.gov
Received 21 November 2011; Revised 23 December 2011; Accepted 13 February 2012
Academic Editor: Alexander McFarlane
Copyright © 2012 Julia A. Golier et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. We obtained pilot data to examine the clinical and neuroendocrine eﬀects of short-term mifepristone treatment in
male veterans with PTSD. Methods. Eight male veterans with military-related PTSD completed a randomized, double-blind trial of
one week of treatment with mifepristone (600mg/day) or placebo. The primary clinical outcome measures were improvement
in PTSD symptoms and dichotomously deﬁned clinical responder status as measured by the CAPS at one-month follow-up.
Additional outcome measures included self-reported measures of PTSD symptom severity, CAPS-2 symptom subscale scores, and
morning plasma cortisol and ACTH levels. Results. Mifepristone was associated with signiﬁcant improvements in total CAPS-2
score. At one-month follow-up, all four veterans in the mifepristone group and one of four veterans in the placebo group achieved
clinical response; three of four veterans in the mifepristone group and one of four veterans in the mifepristone group remitted.
Mifepristone treatment was associated with acute increases in cortisol and ACTH levels and decreases in cytosolic glucocorticoid
receptor number in lymphocytes. Conclusions. Further controlled trials of the eﬀects of mifepristone and their durability are
indicated in PTSD. If eﬀective, a short-term pharmacological treatment in PTSD could have myriad uses.
1.Introduction
Within the last decade, two selective serotonin reuptake in-
hibitors (SSRIs), sertraline and paroxetine, have been ap-
proved by the FDA for the treatment of posttraumatic stress
disorder(PTSD).Instudiesofciviliantraumasurvivors,each
has been superior to placebo in achieving clinical response
and reducing core PTSD symptoms, which represents a sig-
niﬁcant advance. However, their use as PTSD monotherapy
has signiﬁcant limitations. Even in the most favorable stud-
ies, some key symptoms are resistant to treatment (e.g., sleep
disturbance),remissionisuncommon,andcontinuoustreat-
ment is often necessary to prevent relapse. Additionally,
SSRIs have been shown to be largely ineﬀective in combat
veterans with PTSD. There is a need to develop better phar-
macological treatments that speciﬁcally target PTSD symp-
toms and/or pathophysiology. Given the abundant evidence
for hypothalamic-pituitary adrenal (HPA) axis dysregulation
in PTSD, we performed a preliminary study to examine
whether mifepristone—which recalibrates the HPA axis
through peripheral and central mechanisms—could be of
therapeutic beneﬁt.
Mifepristone is a selective antagonist of glucocorticoid
receptors (GRs) that induces increases in cortisol and ad-
renocorticotropin hormone (ACTH) levels through block-
ade of cortisol’s feedback inhibition of the HPA axis. At high
doses, mifepristone has central eﬀects [1, 2]. Mifepristone
and its metabolites appear to retard the rate at which brain
cortisol is expelled via the glycogen pump at the blood-
brain barrier, eﬀectively increasing cortisol levels in the
brain [1, 2]. This acute increase in cortisol leads to an
up-regulation of hippocampal mineralocorticoid receptors
(MRs); re-regulation of the balance of MR and GR receptors
is thought to play a role in the recalibration of the HPA axis
[3, 4] .S i n c eP T S Di sa s s o c i a t e dw i t hg l u c o c o r t i c o i da l t e r -
ations including enhanced glucocorticoid sensitivity [5]a n d
elevated corticotropin releasing factor (CRF) levels [6, 7],
short-term administration of mifepristone may reverse some
of the stress-related neurobiological changes associated with
this disorder and restore homeostasis to this system.
Preliminary data suggest that short-term administration
of high doses of mifepristone can have beneﬁcial eﬀects in
other neuropsychiatric conditions [3, 8–10], but to date mi-
fepristonehasnotbeenstudiedinPTSD.Inthisrandomized,2 Depression Research and Treatment
double-blind, placebo-controlled pilot study, we sought to
collect preliminary data on the clinical and neuroendocrine
eﬀects of short-term (7 day) treatment with high-dose
(600mg/day)mifepristone inveteranswithPTSDinorderto
guide further investigation of its clinical beneﬁts and mecha-
nism of action in PTSD.
2.MaterialsandMethods
Male veteran outpatients who met DSM-IV criteria for
chronic military-related PTSD and who were without a his-
tory of adrenal insuﬃciency (or morning plasma cortisol
<5mcg/dL), diabetes mellitus or endocrinopathy, a history
of moderate to severe traumatic brain injury, stroke, or other
neurological illness, a history of schizophrenia, schizoaﬀec-
tivedisorder,orbipolardisorder,currentsuicidalideation,or
a known allergy to mifepristone were eligible to participate.
Veterans who were taking oral corticosteroids, receiving
specialized trauma-focused psychotherapy, or who were un-
willing to use eﬀective contraceptive methods during the
study were excluded. Veterans receiving psychotropic medi-
cations for PTSD were eligible to participate if they had been
stabilized at a therapeutic dose for a minimum of six weeks
prior to randomization. The protocol was approved by the
Institutional Review Board of the James J. Peters VA Medical
Center. Written informed consent and HIPAA authorization
were obtained from all participants prior to the initiation of
any study procedures.
Participants underwent a complete diagnostic assess-
ment,includingamedicalhistory,physicalexamination,lab-
oratory testing, and administration of the Clinician Admin-
isteredPTSDScale(CAPS)andtheStructuredClinicalInter-
view for DSM-IV (SCID). Questionnaires were administered
to assess combat exposure severity and characteristics of de-
ployment (combat exposure questionnaire (CEQ)), child-
hood trauma (childhood trauma questionnaire (CTQ)), and
symptoms of depression (beck depression inventory (BDI))
and posttraumatic stress (PTSD checklist (PCL)).
Eligible veterans were randomized to receive mifepri-
stone (600mg/day) or matched placebo for one week (7
days), to be taken at bedtime. The randomization log was
maintained by the VA pharmacy, and both the participant
and research staﬀ were blinded to the treatment assignment.
Clinical assessments were performed at baseline, treatment
endpoint, and four weeks after drug discontinuation. Vital
signs, adverse events, and concomitant medications were
obtained at every visit to monitor safety.
The primary clinical outcome measures were severity of
PTSD symptoms, as measured by the total severity score of
the CAPS-2, and dichotomously deﬁned clinical responder
status. The liberal responder criterion, deﬁned as a 12-point
or greater reduction in total CAPS-2 score, reﬂects reliable
clinical changes in veterans with PTSD. The more conser-
vative criterion, a 30% or greater reduction in total CAPS-
2 score, is a frequently used deﬁnition in PTSD clinical
trials. Secondary clinical outcome measures included self-
reported symptoms as measured by the PCL and the BDI,
and the three PTSD symptom subscale scores from the
CAPS-2 (intrusive symptoms, avoidance symptoms, and hy-
perarousal symptoms). Dichotomous remitter status, de-
ﬁned as no longer meeting diagnostic criteria for PTSD at
four-week follow-up, was also explored.
Morning plasma cortisol and ACTH levels and GR bind-
ing per cell were measured as indicators of the magnitude of
mifepristone’s eﬀects on negative feedback inhibition. The
lysozyme IC50-DEX was used to measure mifepristone’s antag-
onism of peripheral GR sensitivity [5].
Measures of central tendency and variability (mean and
SD) were calculated at treatment baseline, endpoint, and
four-week follow-up for all continuous primary and secon-
dary outcome measures. Baseline comparisons of group dif-
ferences were conducted using independent samples t-tests
for continuous variables and chi-square analysis for categor-
ical variables. Changes within groups for the primary and
secondary outcome measures were analyzed using a series of
paired samples t-tests, pairing initial rating and endpoint or
four-week follow-up. For between groups-analysis, changes
in primary and secondary outcome measures were analyzed
using independent samples t-tests. The Mann-Whitney U
test, which compares the sum of the ranks and is less likely to
be inﬂuenced by outliers, was used to assess whether ﬁndings
from the independent samples t-tests remained signiﬁcant
when nonparametric methods were employed. The dichoto-
mous clinical response and remitter status variables were
analyzed using chi-square analysis. All tests were two sided
with statistical signiﬁcance set at P<0.05.
3. Results
Thirteen veterans were enrolled in the clinical trial; three
werelosttofollow-uporfoundtobeineligible,onewithdrew
prior to randomization, nine were randomized, and eight
completed study procedures. For completers (n = 8), the
mean (SD) age was 48.88 (12.68) years (range 26–63 years).
With respect to race and ethnicity, 12.5% were Caucasian,
75% were African American, and 12.5% chose not to id-
entify their race; 25% were Hispanic. The mean level of
education was 13.5 (2.39) years. Four participants served in
the Vietnam or post-Vietnam era, and four participants were
Operation Iraqi Freedom/Operation Enduring Freedom
(OIF/OEF) veterans. The mean score on the CEQ at screen-
ing was 55.88 (12.26), indicating moderate exposure to com-
bat stress. As shown in Table 1, there were no signiﬁcant dif-
ferences between groups for multiple clinical variables at
baseline.
Based on the clinical response deﬁnition of a 12-point or
greater decrease in total CAPS-2 score from initial evalua-
tion,threeoffourveteransinthemifepristonegroupandtwo
of four veterans in the placebo group achieved clinical re-
sponse at treatment endpoint (P = 0.465). At one-month
follow-up, all four veterans in the mifepristone group and
oneoffourveteransintheplacebogroupachievedclinicalre-
sponse(P = 0.028).Similarimprovementswereobservedus-
ing the clinical response deﬁnition of a 30% change in total
CAPS-2 score; three of four veterans in the mifepristone
group achieved clinical response at treatment endpoint com-
pared to one of four in the placebo group (P = 0.157).Depression Research and Treatment 3
Table 1: Clinical and neuroendocrine outcomes.
Pre-treatment Post-treatment Between Groups Signiﬁcance
Initial Endpoint 4-week Initial to
endpoint
Initial to
4-week
Mean (SD) Mean (SD) Mean (SD) P value P value
Clinical
CAPS Score Drug (n = 4) 68.75 (10.24) 43.50 (19.49) 44.00 (24.12)
0.425 0.047a
Placebo (n = 4) 68.25 (8.77) 56.50 (31.89) 65.25 (18.86)
Intrusive Sx Drug (n = 4) 13.75 (8.06) 8.00 (7.70) 7.50 (9.00)
0.463 0.126
Placebo (n = 4) 14.50 (4.65) 12.00 (10.30) 15.00 (9.42)
Avoidance Sx Drug (n = 4) 29.25 (7.14) 18.75 (11.44) 17.00 (10.74)
0.239 0.027b
Placebo (n = 4) 28.50 (1.29) 25.50 (7.05) 26.00 (5.72)
Hyperarousal Sx Drug (n = 4) 25.75 (0.50) 16.75 (5.56) 19.50 (9.68)
0.786 0.359
Placebo (n = 4) 25.25 (6.40) 18.25 (10.53) 24.25 (5.97)
BDI Drug (n = 4) 22.25 (5.85) 13.25 (4.72) 11.50 (9.15)
0.124 0.769
Placebo (n = 4) 24.25 (12.12) 24.75 (10.05) 23.75 (9.54)
PCL Drug (n = 4) 60 (10.83) 46.75 (11.79) 49.25 (15.59)
0.691 0.200
Placebo (n = 4) 63.25 (11.41) 54.25 (24.17) 56.25 (16.68)
Neuroendocrine
Cortisol (µg/dL) Drug (n = 4) 13.15 (3.52) 31.28 (5.49) 11.53 (4.27)
0.001c 0.786
Placebo (n = 4) 12.43 (6.16) 12.90 (4.87) 11.83 (2.91)
ACTH (pg/mL) Drug (n = 4) 49.33 (29.69) 153.45 (40.25) 53.63 (8.08)
0.009d 0.785
Placebo (n = 4) 30.88 (14.83) 38.40 (16.18) 41.63 (19.33)
Lysozyme IC50
(nM)
Drug (n = 2) 8.00 (2.55) 5.57 (.76) 6.73 (3.66)
0.162 0.411
Placebo (n = 4) 3.27 (2.89) 3.65 (2.06) 5.03 (1.68)
GR/cell Drug (n = 3) 1557.67 (539.75) 188.67 (116.89) 1593.00 (770.02)
0.003 0.322
Placebo (n = 4) 1019.50 (553.91) 1243.00 (543.84) 1824.75 (683.80)
aMedian change in CAPS score for mifepristone group (20.0); median change in CAPS score for placebo group (10.5); nonparametric P value (0.021).
bMedian change in CAPS avoidance symptom score for mifepristone group (11.0); median change in CAPS avoidance symptom score for placebo group
(4.0); nonparametric P value (0.028).
cMedian change in cortisol for mifepristone group (17.2); median change in cortisol for placebo group (0.4); nonparametric P value (0.021).
dMedian change in ACTH for mifepristone group (90.6); median change ACTH for placebo group (4.2); nonparametric P value (0.021).
At one-month follow-up, two of four veterans in the mif-
epristone group and no veterans in the placebo group
maintained clinical response (P = 0.102). With respect to
remitterstatus,oneoffourveteransintheplacebogroupand
three of four veterans in the mifepristone group no longer
met diagnostic criteria for PTSD at four-week follow-up
(P = 0.157).
ClinicaldataareshowninTable 1 forparticipants treated
withmifepristoneorplacebo.Betweengroupsanalysisshow-
ed that the mifepristone group had signiﬁcantly greater im-
provement in total CAPS-2 score (P = 0.047) at one-month
follow-up when compared to the placebo group. Using the
Mann-Whitney U test, our ﬁndings were similar to those
obtained using parametric methods, with signiﬁcant im-
provement in total CAPS score (P = 0.021) across groups
from screening to four-week follow-up. The mifepristone
group also had a signiﬁcantly greater improvement in
CAPS-2 avoidance symptom scores at four-week follow-up
when analyzed with both parametric (P = 0.027) and non-
parametric (P = 0.028) methods. Within-groups analysis
showed a signiﬁcant decrease in total CAPS-2 score from
initial evaluation to four-week follow-up (P = 0.039) in the
mifepristone group; this included signiﬁcant decreases in
intrusive symptom score (P = 0.001) and avoidance symp-
tom score (P = 0.008). There were no signiﬁcant changes in
total CAPS-2 score or CAPS-2 symptom subscale scores
within the placebo group. The mifepristone group also had
a signiﬁcant decrease in PCL score at four-week follow-up
(P = 0.036). There were no signiﬁcant diﬀerences between
groups for improvement in PCL or BDI scores.
Neuroendocrine outcomes are also presented in Table 1;
signiﬁcant changes in plasma cortisol (P = 0.007), ACTH
(P = 0.009), and GR binding (P = 0.041) from baseline to
treatment endpoint were observed within the mifepristone
group. There were no signiﬁcant biological changes in the
placebogroup,andneithergroupshowedsigniﬁcantchanges
in lysozyme IC50-DEX. Between-groups analysis revealed sig-
niﬁcant diﬀerences in changes in cortisol (P = 0.001),
ACTH (P = 0.009), and GR binding (P = 0.003) from ba-
selinetotreatmentendpoint.Nonparametrictestsalsofound
signiﬁcant diﬀerences between groups for the change in
cortisol (P = 0.021) and ACTH (P = 0.021) from baseline to
treatment endpoint. There were no signiﬁcant changes with-
ingroupsorbetweengroupsforcortisol,ACTH,GRbinding,
or lysozyme IC50-DEX at one-month follow-up.
No side eﬀects, adverse events, or serious adverse events
were reported by participants in either treatment condition.4 Depression Research and Treatment
4. Discussion
This is the ﬁrst study to examine mifepristone in PTSD. In
these preliminary data, mifepristone was signiﬁcantly more
eﬀective than placebo based on the primary outcomes of
clinical responder status and PTSD symptom severity. Rates
of remission were also higher in the mifepristone group
than the placebo group. Interestingly, these beneﬁcial eﬀects
were more marked at four-week follow-up than at treatment
endpoint, suggesting that the results do not merely reﬂect an
acute change in neurohormonal activity. The precise central
mechanism of action of mifepristone is not known.
Indeed, mifepristone induced acute increases in cortisol
and ACTH levels, as would be predicted by blockade of
negative feedback inhibition. To our knowledge, this is the
ﬁrst study that also demonstrates changes in glucocorticoid
receptor number in lymphocytes with mifepristone. Since
cytosolic GR declined substantially following mifepristone
administration, the data raise the possibility that the acute
increase in cortisol levels may have increased binding to
cytosolic GR, resulting in greater translocation to cell nuclei
and enhanced glucocorticoid signaling. At four-week follow-
up, the acute neurohormonal changes had resolved, but ben-
eﬁcial clinical eﬀects were evident. These ﬁndings may reﬂect
someformofrecalibrationoftheHPAaxis;mifepristonealso
impairs consolidation of fear memory [11] and may directly
or indirectly exert eﬀects on the inﬂammatory cascade [12],
both of which could be therapeutic in PTSD.
The results of this pilot study are limited by the small
sample size and all the male veteran sample. Additionally,
half of all study participants were veterans of the Vietnam
or post-Vietnam era; these veterans may have had PTSD of a
much longer duration when compared to OIF/OEF veterans,
which may confound the results of the study. However, this
clinical trial had a high retention rate and no adverse events
or complaints about study procedures, suggesting that mif-
epristone treatment is safe, tolerable, and acceptable to
veterans with PTSD, as has been found in other populations.
The positive ﬁndings of this pilot clinical trial provide an
important proof of the concept that treatment with mifepri-
stone is a feasible strategy for improving clinical outcomes in
veterans with PTSD; accordingly, further study is indicated.
Should this neuroendocrine agent yield evidence of eﬃcacy
in PTSD, there are many potential uses which could be
explored: as single or intermittent monotherapy in patients
reluctant to take long-term medications, as an adjunct to
pharmacotherapy, psychotherapy, or other standard treat-
ments, or as prophylaxis in acutely traumatized persons.
5. Conclusions
Additional funding is needed to conduct a larger, multisite
trial of mifepristone in veterans with PTSD to determine if
this medication is an eﬀective psychopharmacological treat-
ment option for PTSD.
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